What is the appropriate treatment for a 56-year-old patient with acute myeloid leukemia (AML) who has a complex karyotype including monosomy 7 and is minimal residual disease (MRD) negative after induction therapy?

Allogeneic Hematopoietic Cell Transplantation (alloHCT) in First Complete Remission

This 56-year-old patient with AML harboring complex karyotype including monosomy 7 should proceed directly to allogeneic hematopoietic cell transplantation (alloHCT) in first complete remission (CR1), despite achieving MRD-negative status after induction. Complex karyotype with monosomy 7 definitively places this patient in the ELN adverse-risk category, and alloHCT remains the only consolidation strategy with curative potential for this high-risk disease 1.

Why AlloHCT Despite MRD Negativity?

The adverse-risk cytogenetics—particularly complex karyotype with monosomy 7—fundamentally drives the treatment decision here, superseding the favorable MRD status. While MRD negativity is prognostically encouraging, it does not change the underlying biology of adverse-risk disease or eliminate the high relapse risk inherent to complex karyotype AML.

The ESMO guidelines explicitly state that patients in CR with ELN intermediate- or adverse-risk AML should undergo alloHCT if feasible [II, A] 1. This recommendation applies regardless of MRD status at the time of consolidation decision-making.

Pre-Transplant Consolidation Approach

Before proceeding to alloHCT:

• Administer at least 1-2 cycles of consolidation chemotherapy while donor search and transplant logistics are arranged 1
• Standard consolidation consists of intermediate-dose cytarabine (IDAC): 1.5 g/m² every 12 hours on days 1-3 for patients <60-65 years 1
• Alternative intensive consolidation with MACE/MidAC (amsacrine, cytarabine, etoposide/mitoxantrone) may be considered if alloHCT will be delayed, as this showed 39% OS versus 0% in adverse-risk patients not receiving transplant 1

The timing of alloHCT is typically determined by donor availability rather than a fixed number of consolidation cycles 1.

Transplant Considerations for This Patient

Donor Selection Priority

At age 56, this patient should receive:

1. First priority: HLA-identical sibling or matched unrelated donor (10/10 or 9/10 match) if search time <3 months 1
2. Second/third priority: Umbilical cord blood or haploidentical donor based on center experience 1

Conditioning Regimen

Myeloablative conditioning (MAC) is recommended for this 56-year-old patient if HCT-CI score <2 and no significant comorbidities are present 1:

• Preferred MAC regimen: Fludarabine/busulfan (Flu/Bu4), which shows less toxicity than busulfan/cyclophosphamide while maintaining efficacy 1
• Alternative: Cyclophosphamide/TBI or Bu/Cy regimens are acceptable 1
• Reduced-intensity conditioning (RIC) should be reserved for patients with HCT-CI ≥2 or significant comorbidities 1

MAC is preferred over RIC in younger fit patients (≤55-60 years) as it provides better disease control, though this patient at age 56 sits at the upper boundary where careful comorbidity assessment is critical 1.

MRD Status and Post-Transplant Strategy

The MRD-negative status after induction is prognostically favorable but does not eliminate transplant indication. However, it does inform post-transplant monitoring strategy:

Post-Transplant MRD Monitoring

• Serial MRD assessment post-alloHCT is recommended to detect early molecular relapse 2, 3, 4
• MRD positivity post-transplant warrants pre-emptive intervention before overt hematologic relapse 2, 4

Post-Transplant Maintenance/Pre-emptive Therapy

Current evidence for routine post-transplant maintenance in MRD-negative patients remains controversial 2, 1:

• Hypomethylating agents (HMAs) like azacitidine are under investigation but cannot be routinely recommended outside clinical trials for prophylactic use 1
• Pre-emptive therapy should be reserved for MRD recurrence post-transplant rather than universal prophylaxis 2
• Venetoclax plus azacitidine shows particular efficacy for MRD failure post-transplant and is being studied in the VIALE-T trial (NCT04161885) 2
• Immunological interventions (DLI, immunosuppression reduction) may be considered for MRD positivity post-transplant, though evidence is limited 2

Critical Pitfalls to Avoid

1. Do not delay or forego alloHCT based on MRD-negative status in adverse-risk disease—the cytogenetic risk profile takes precedence
2. Do not substitute chemotherapy consolidation or autologous HCT for alloHCT in this adverse-risk patient—outcomes are dramatically inferior (0% OS without transplant in some series) 1
3. Do not use maintenance therapy as a substitute for alloHCT in transplant-eligible candidates 1
4. Ensure timely transplant referral—donor search should begin immediately upon achieving CR to minimize time to transplant 1

If AlloHCT Is Not Feasible

Only if alloHCT is contraindicated or no suitable donor is available:

• Consolidation chemotherapy with IDAC (minimum 2 cycles) 1
• Consider MACE/MidAC for younger patients with adverse cytogenetics 1
• Autologous HCT is an inferior alternative but superior to chemotherapy alone in some intermediate-risk patients; however, data in adverse-risk disease are poor 1

The MRD-negative status provides some reassurance but does not fundamentally alter the dismal prognosis of complex karyotype AML without allogeneic transplantation.